Novo Nordisk A S annual total assets
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Total Assets Growth & History (NVO)
Novo Nordisk A S's total assets was kr542.90B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr542.90B | kr77.27B | +16.60% |
| 2024 | 2024-12-31 | kr465.63B | kr151.14B | +48.06% |
| 2023 | 2023-12-31 | kr314.49B | kr73.23B | +30.35% |
| 2022 | 2022-12-31 | kr241.26B | kr46.75B | +24.03% |
| 2021 | 2021-12-31 | kr194.51B | kr49.59B | +34.22% |
| 2020 | 2020-12-31 | kr144.92B | kr19.31B | +15.37% |
| 2019 | 2019-12-31 | kr125.61B | — | — |
Novo Nordisk A S quarterly total assets
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr594.94B | kr112.79B | +23.39% |
| Q1 2026 | 2026-03-31 | kr559.22B | — | — |
| Q4 2025 | 2025-12-31 | kr542.90B | kr77.27B | +16.60% |
| Q3 2025 | 2025-09-30 | kr512.29B | — | — |
| Q2 2025 | 2025-06-30 | kr482.15B | — | — |
| Q4 2024 | 2024-12-31 | kr465.63B | kr151.14B | +48.06% |
| Q4 2023 | 2023-12-31 | kr314.49B | kr73.23B | +30.35% |
| Q4 2022 | 2022-12-31 | kr241.26B | kr46.75B | +24.03% |
| Q4 2021 | 2021-12-31 | kr194.51B | kr49.59B | +34.22% |
| Q4 2020 | 2020-12-31 | kr144.92B | — | — |
Novo Nordisk A S total assets trends
Over the last five fiscal years, Novo Nordisk A S's total assets increased from kr144.92B to kr542.90B, a change of kr397.98B. The latest reported quarter, Q2 2026, shows kr594.94B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...